Sermorelin, CJC-1295 No DAC and Tesamorelin are all analogues of growth hormone-releasing hormone, and all three act at the same receptor. What separates them is how much of the native 44-residue sequence each keeps and how it has been modified. Sermorelin is the unmodified first 29 residues, CJC-1295 No DAC is the same stretch with four substitutions, and Tesamorelin is the full sequence with a modified N-terminus.
At a glance
| Sermorelin | CJC-1295 No DAC | Tesamorelin | |
|---|---|---|---|
| Length | 29 amino acids | 29 amino acids | 44 amino acids |
| Relation to GHRH | GHRH (1-29) amide, unmodified | GHRH (1-29) with four substitutions | GHRH (1-44) amide |
| Modification | None | D-Ala2, Gln8, Ala15, Leu27 | Trans-3-hexenoyl group on the N-terminal tyrosine |
| Receptor | GHRH receptor | GHRH receptor | GHRH receptor |
| NuVion vial sizes | 5mg | 10mg | 10mg and 20mg |
Structure
Human GHRH is 44 amino acids long, and its activity at the receptor sits in the first 29. Sermorelin is exactly that stretch with an amidated C-terminus, which makes it the shortest fragment that keeps full activity.
CJC-1295 No DAC starts from the same 29 residues and changes four of them. The substitutions remove the sites where the native sequence is cut by dipeptidyl peptidase or oxidised, so the peptide lasts longer in solution. Tesamorelin takes the other approach. It keeps all 44 residues and protects the N-terminus with a trans-3-hexenoyl group in place of substituting amino acids.
Mechanism at the receptor level
All three bind the GHRH receptor on pituitary somatotrophs, a class B G protein-coupled receptor that signals through Gs, adenylyl cyclase, cyclic AMP and protein kinase A. Because the target is shared, the three are used as a matched series. Running them in parallel shows how chain length and N-terminal protection change stability and receptor activation in the same assay.
Where each is used in research
- Sermorelin: reference GHRH (1-29) ligand in cyclic AMP and growth hormone release assays
- CJC-1295 No DAC: stability comparisons against the unmodified sequence
- Tesamorelin: full-length reference compound in cyclic AMP and protein kinase A signalling assays
- All three: GHRH receptor binding and activation studies in somatotroph cultures
Supplied by NuVion
NuVion stocks all three in Australia as lyophilised vials: Sermorelin in 5mg, CJC-1295 No DAC in 10mg and Tesamorelin in 10mg and 20mg. Sermorelin and CJC-1295 No DAC are both part of the Somatotropic Axis Set. Published certificates are shown on each product page and in the COA library. For the ghrelin receptor side of the same axis, see CJC-1295 vs Ipamorelin.
Frequently asked questions
What is the difference between Sermorelin and CJC-1295?
Four amino acids. Both are 29 residues long and based on GHRH (1-29). Sermorelin is the unmodified sequence, and CJC-1295 No DAC carries substitutions at positions 2, 8, 15 and 27.
How is Tesamorelin different from Sermorelin?
Tesamorelin is the full 44-residue GHRH sequence with a trans-3-hexenoyl group on its N-terminus. Sermorelin is the first 29 residues with no modification beyond the C-terminal amide.
Are these products therapeutic goods in Australia?
No. NuVion’s Sermorelin, CJC-1295 No DAC and Tesamorelin are laboratory chemicals for in vitro research. They are not included in the Australian Register of Therapeutic Goods, have not been assessed by the Therapeutic Goods Administration, and are not for human or veterinary use.
Research use only. These products are laboratory chemicals supplied for in vitro research. They are not included in the Australian Register of Therapeutic Goods and have not been assessed by the Therapeutic Goods Administration for quality, safety or efficacy. They are not for human or veterinary use, and nothing on this page is a representation about therapeutic use.